What Novanta Does & How It Makes Money (NOVT)
Updated October 2026 · reflects Novanta's latest reported financials
Maker of precision laser, motion and medical technology components. Novanta designs, manufactures and sells precision components and subsystems to equipment makers in industrial, robotics, life science and medical markets.
How Novanta makes money
Novanta designs, manufactures and sells precision components and subsystems to equipment makers in industrial, robotics, life science and medical markets. It also earns revenue from medical devices and the related disposables used with them.
What Novanta does
Novanta Inc., formerly GSI Group and based in Bedford, Massachusetts, supplies precision technologies that serve as key components in other companies' equipment. One segment covers precision medicine and manufacturing. It makes laser beam steering and scanning systems, laser sources, robotic and precision motion products, end-of-arm tooling and bearing spindles for advanced industrial processes, industrial and medical robotics, life science automation and medical laser procedures such as ophthalmology. The Medical Solutions segment offers medical-grade technologies, including insufflators, pumps and disposables, imaging, identification and RFID solutions, advanced motion control, light engines and integrated operating room technology. The company was founded in 1968 and sells in the United States and internationally.
Products & services
- Laser beam steering and scanning solutions
- Laser sources
- Robotic and precision motion systems and robotic end-of-arm tooling
- Medical insufflators, pumps and related disposables
- Imaging, identification and RFID solutions
- Integrated operating room technologies and light engines
What is Novanta worth?
On an owner-earnings DCF, Novanta's most-likely value is about $93 versus a recent price near $141 (34% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$37) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
NOV (NOV) · Novavax (NVAX) · LivaNova (LIVN) · Xi'an NovaStar Tech (301589.SZ) · Nordson (NDSN)
TacticScale